Pfizer‘s (NYSE: PFE) and Moderna‘s (NASDAQ: MRNA) COVID-19 vaccines are rolling out — but not as smoothly as hoped. In this Fintech Zoom Live video recorded on Jan. 13, 2021, Healthcare and Cannabis Bureau Chief Corinne Cardina and Fool.com writer Keith Speights discuss the biggest hurdles for COVID-19 vaccinations so far.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Fintech Zoom Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and Pfizer wasn’t one of them! That’s right — they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of November 20, 2020
Corinne Cardina: We’re starting to see the vaccination be expanded beyond that initial priority group, which was healthcare workers and long term care residents and staff. The CDC has expanded their guidance to now include people who are 65 and older. That is a big change. There’s been a couple of other changes that we’ll get into.
But let’s talk about the disconnect, in what is being called the last mile of vaccinations. Doses are being distributed, it’s a challenge to get them into arms. What are some of the hurdles involved here? Of course, the government has said there’s a lag in the data. That is one inherent problem with those distribution vaccination numbers we have. But what’s the actual logistical hurdles?
Keith Speights: Some of the hurdles I think are now in the rearview mirror. For example, during the month of December, early January, we had two significant holidays. You had a lot of healthcare workers taking vacations. There weren’t as many workers available to administer the doses and not as many people lining up to get the doses during the holidays like that. That’s one of the factors that’s caused the numbers to not grow as much as we would have liked.
But the bigger issue, really, I think there are two big issues. One is just lack of coordination between the federal government and the states. There’s been not a great hand-off during the federal government and the different state governments. Then there’s just a money issue, Corinne, where quite a few states and local health officials are just saying, we don’t have enough money to do all we need to do. That’s certainly an issue and certainly a challenge for the states that are trying to get these vaccines out to their residents.
Corinne Cardina: Definitely. Another question has been at what point do you move off that first priority list and begin vaccinating people in maybe tier-2. Last week Department of Health and Human Services Secretary Azar and FDA Commissioner Dr. Hahn, they told states to start expanding vaccines to the lower priority groups instead of waiting to get most frontline healthcare workers vaccinated. Some states were holding off. Maybe they only had 30 percent of that group vaccinated and trying to get more. They’re saying, let’s go ahead and open up those appointments and try to get more people in different groups vaccinated rather than waiting.
Corinne Cardina has no position in any of the stocks mentioned. Keith Speights owns shares of Pfizer. The Fintech Zoom has no position in any of the stocks mentioned. The Fintech Zoom has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.